We focused on NB samples since the LINES study is one of the very first clinical trials worldwide to explore the usability of a series of SCAs in addition to information on MYCN copy number in the decision making process [12] and the feasibility of identification of possible new prognostic genomic changes. Here, MYCN is linked to neuroblastoma.